What is Zacks Research’s Forecast for RDY FY2025 Earnings?

Dr. Reddy’s Laboratories Limited (NYSE:RDY) – Stock analysts at Zacks Research upped their FY2025 earnings per share (EPS) estimates for Dr. Reddy’s Laboratories in a research report issued on Tuesday, November 26th. Zacks Research analyst R. Department now expects that the company will post earnings of $0.81 per share for the year, up from their previous estimate of $0.80. The consensus estimate for Dr. Reddy’s Laboratories’ current full-year earnings is $0.83 per share. Zacks Research also issued estimates for Dr. Reddy’s Laboratories’ Q4 2025 earnings at $0.23 EPS, Q1 2026 earnings at $0.20 EPS, Q2 2026 earnings at $0.21 EPS, Q3 2026 earnings at $0.21 EPS, Q4 2026 earnings at $0.22 EPS, FY2026 earnings at $0.84 EPS, Q1 2027 earnings at $0.18 EPS and Q2 2027 earnings at $0.16 EPS.

A number of other equities analysts have also commented on RDY. Barclays decreased their price target on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating on the stock in a report on Wednesday, November 6th. StockNews.com cut Dr. Reddy’s Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 13th.

Dr. Reddy’s Laboratories Trading Down 0.4 %

Shares of RDY opened at $14.08 on Thursday. Dr. Reddy’s Laboratories has a 1-year low of $12.90 and a 1-year high of $16.89. The company has a market capitalization of $11.75 billion, a P/E ratio of 22.49 and a beta of 0.56. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.36. The firm’s 50 day simple moving average is $15.27 and its 200 day simple moving average is $15.34.

Institutional Trading of Dr. Reddy’s Laboratories

Several hedge funds and other institutional investors have recently bought and sold shares of RDY. Farther Finance Advisors LLC lifted its holdings in shares of Dr. Reddy’s Laboratories by 43.2% in the 3rd quarter. Farther Finance Advisors LLC now owns 454 shares of the company’s stock worth $36,000 after acquiring an additional 137 shares during the last quarter. Venturi Wealth Management LLC purchased a new position in Dr. Reddy’s Laboratories in the 3rd quarter worth $60,000. Van ECK Associates Corp raised its position in Dr. Reddy’s Laboratories by 64.3% in the 3rd quarter. Van ECK Associates Corp now owns 823 shares of the company’s stock worth $64,000 after purchasing an additional 322 shares during the period. GAMMA Investing LLC lifted its stake in Dr. Reddy’s Laboratories by 83.2% in the third quarter. GAMMA Investing LLC now owns 1,447 shares of the company’s stock worth $115,000 after purchasing an additional 657 shares during the last quarter. Finally, Glenmede Trust Co. NA purchased a new stake in Dr. Reddy’s Laboratories during the third quarter valued at about $207,000. Hedge funds and other institutional investors own 14.02% of the company’s stock.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.